These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31215145)

  • 1. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma.
    Zhou Q; Li W; Kong D; Liu Z; Shi Z; Ma X; Li Y; Jiang J
    Cancer Med; 2019 Aug; 8(9):4380-4388. PubMed ID: 31215145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y; Tong J; Ai Z; Wang J; Teng Y
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
    Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
    Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
    Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
    Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
    Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
    PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DACH1 suppresses breast cancer as a negative regulator of CD44.
    Xu H; Yu S; Yuan X; Xiong J; Kuang D; Pestell RG; Wu K
    Sci Rep; 2017 Jun; 7(1):4361. PubMed ID: 28659634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of the epithelial-mesenchymal transition by SHARP1 is linked to the NOTCH1 signaling pathway in metastasis of endometrial cancer.
    Liao Y; He X; Qiu H; Che Q; Wang F; Lu W; Chen Z; Qiu M; Wang J; Wang H; Wan X
    BMC Cancer; 2014 Jul; 14():487. PubMed ID: 24997474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway.
    Ai Z; Wang J; Wang Y; Lu L; Tong J; Teng Y
    Cancer; 2010 Aug; 116(15):3603-13. PubMed ID: 20564127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
    Zhao S; Chen X; Lu X; Yu Y; Feng Y
    Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DACH1, a novel target of miR-218, participates in the regulation of cell viability, apoptosis, inflammatory response, and epithelial-mesenchymal transition process in renal tubule cells treated by high-glucose.
    Zhang YL; Wang JM; Yin H; Wang SB; He CL; Liu J
    Ren Fail; 2020 Nov; 42(1):463-473. PubMed ID: 32408786
    [No Abstract]   [Full Text] [Related]  

  • 11. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner.
    Shao S; Zhao X; Zhang X; Luo M; Zuo X; Huang S; Wang Y; Gu S; Zhao X
    Mol Cancer; 2015 Feb; 14(1):28. PubMed ID: 25645291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line.
    Li W; Wang S; Qiu C; Liu Z; Zhou Q; Kong D; Ma X; Jiang J
    J Transl Med; 2019 Feb; 17(1):58. PubMed ID: 30813939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
    Zhang Z; Dong L; Sui L; Yang Y; Liu X; Yu Y; Zhu Y; Feng Y
    Int J Gynecol Cancer; 2011 Feb; 21(2):213-21. PubMed ID: 21270604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
    Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
    Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling.
    Hu X; Zhang L; Li Y; Ma X; Dai W; Gao X; Rao X; Fu G; Wang R; Pan M; Guo Q; Xu X; Zhou Y; Gao J; Zhang Z; Cai S; Peng J; Hua G
    EBioMedicine; 2020 Jun; 56():102800. PubMed ID: 32512510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cells.
    Lee II; Maniar K; Lydon JP; Kim JJ
    Oncogene; 2016 Sep; 35(39):5191-201. PubMed ID: 26996671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
    Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
    Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of DACH1 activity by short hairpin RNA represses cell proliferation and tumor invasion in pancreatic cancer.
    Bu XN; Qiu C; Wang C; Jiang Z
    Oncol Rep; 2016 Aug; 36(2):745-54. PubMed ID: 27278537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
    Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.